Sökning: onr:"swepub:oai:DiVA.org:uu-516106" >
Appraisal of the ca...
-
Larsson, Susanna C.Karolinska Institutet,Uppsala universitet,Medicinsk epidemiologi,Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
(författare)
Appraisal of the causal effect of plasma caffeine on adiposity, type 2 diabetes, and cardiovascular disease : two sample mendelian randomisation study
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
2023-03-30
-
BMJ Publishing Group Ltd,2023
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-516106
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-516106URI
-
https://doi.org/10.1136/bmjmed-2022-000335DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:236936261URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
OBJECTIVE: To investigate the potential causal effects of long term plasma caffeine concentrations on adiposity, type 2 diabetes, and major cardiovascular diseases.DESIGN: Two sample mendelian randomisation study.SETTING: Genome-wide association study summary data for associations of two single nucleotide polymorphisms associated with plasma caffeine at the genome-wide significance threshold (rs2472297 near the CYP1A2 gene and rs4410790 near the AHR gene) and their association with the outcomes.PARTICIPANTS: Primarily individuals of European ancestry participating in cohorts contributing to genome-wide association study consortia.MAIN OUTCOME MEASURES: Outcomes studied were body mass index, whole body fat mass, whole body fat-free mass, type 2 diabetes, ischaemic heart disease, atrial fibrillation, heart failure, and stroke.RESULTS: Higher genetically predicted plasma caffeine concentrations were associated with lower body mass index (beta -0.08 standard deviation (SD) (95% confidence interval -0.10 to -0.06), where 1 SD equals about 4.8 kg/m2 in body mass index, for every standard deviation increase in plasma caffeine) and whole body fat mass (beta -0.06 SD (-0.08 to -0.04), 1 SD equals about 9.5 kg; P<0.001) but not fat-free mass (beta -0.01 SD (-0.02 to -0.00), 1 SD equals about 11.5 kg; P=0.17). Higher genetically predicted plasma caffeine concentrations were associated with a lower risk of type 2 diabetes in two consortia (FinnGen and DIAMANTE), with a combined odds ratio of 0.81 ((95% confidence interval 0.74 to 0.89); P<0.001). Approximately half (43%; 95% confidence interval 30% to 61%) of the effect of caffeine on type 2 diabetes was estimated to be mediated through body mass index reduction. No strong associations were reported between genetically predicted plasma caffeine concentrations and a risk of any of the studied cardiovascular diseases.CONCLUSIONS: Higher plasma caffeine concentrations might reduce adiposity and risk of type 2 diabetes. Further clinical study is warranted to investigate the translational potential of these findings towards reducing the burden of metabolic disease.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Woolf, Benjamin
(författare)
-
Gill, Dipender
(författare)
-
Uppsala universitetMedicinsk epidemiologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:BMJ medicine: BMJ Publishing Group Ltd2:12754-0413
Internetlänk
Hitta via bibliotek
Till lärosätets databas